Back to the Future of Psychopharmacology The section about new and potential psychopharmacologic treatments in psychiatry.Povratak u budućnost psihofarmakologije. Rubrika o novim i potencijalnim molekulama za primjenu u psihijatriji
Glycine is a noncompetitive co-agonist of NMDA receptor, ionotropic receptor of glutamatergic brain ...
Schizophrenia is a severe mental illness characterized by behavioral and cognitive symptoms. Several...
Reduced activity of the N-methyl-D-aspartate receptor (NMDAR) has been implicated in the pathophysio...
Back to the Future of Psychopharmacology The section about new and potential psychopharmacologic tre...
Schizophrenia is a severe mental illness that affects ~1% of the world's population. It is clinicall...
A section focused on potential and new psychopharmacologic treatment optionsRubrika o potencijalnim ...
Treatment-resistant schizophrenia (TRS) or suboptimal response to antipsychotics affects almost 30% ...
Antipsychotics are the mainstay of schizophrenia treatment. However, approximately one third of schi...
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a cla...
Psychopharmacology of schizophrenia has remained static for many years because the mechanisms explor...
Schizophrenia is a debilitating mental illness which involves three groups of symptoms, i.e., positi...
© Cambridge University Press 2019. Schizophrenia remains one of the most severe medical diseases. Cu...
Adaptive purposeful behaviour depends on appropriate modifications of synaptic connectivity that inc...
Schizophrenia is a severe and chronic disease, leading to important social and physical consequences...
Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical compani...
Glycine is a noncompetitive co-agonist of NMDA receptor, ionotropic receptor of glutamatergic brain ...
Schizophrenia is a severe mental illness characterized by behavioral and cognitive symptoms. Several...
Reduced activity of the N-methyl-D-aspartate receptor (NMDAR) has been implicated in the pathophysio...
Back to the Future of Psychopharmacology The section about new and potential psychopharmacologic tre...
Schizophrenia is a severe mental illness that affects ~1% of the world's population. It is clinicall...
A section focused on potential and new psychopharmacologic treatment optionsRubrika o potencijalnim ...
Treatment-resistant schizophrenia (TRS) or suboptimal response to antipsychotics affects almost 30% ...
Antipsychotics are the mainstay of schizophrenia treatment. However, approximately one third of schi...
Glycine transporters are endogenous regulators of the dual functions of glycine, which acts as a cla...
Psychopharmacology of schizophrenia has remained static for many years because the mechanisms explor...
Schizophrenia is a debilitating mental illness which involves three groups of symptoms, i.e., positi...
© Cambridge University Press 2019. Schizophrenia remains one of the most severe medical diseases. Cu...
Adaptive purposeful behaviour depends on appropriate modifications of synaptic connectivity that inc...
Schizophrenia is a severe and chronic disease, leading to important social and physical consequences...
Glycine transporter-1 (GlyT1) inhibition has been extensively studied both in pharmaceutical compani...
Glycine is a noncompetitive co-agonist of NMDA receptor, ionotropic receptor of glutamatergic brain ...
Schizophrenia is a severe mental illness characterized by behavioral and cognitive symptoms. Several...
Reduced activity of the N-methyl-D-aspartate receptor (NMDAR) has been implicated in the pathophysio...
DOI
Add to ORKG